Personalis (NASDAQ:PSNL) PT Lowered to $30.00 at HC Wainwright

Personalis (NASDAQ:PSNLGet Rating) had its price objective decreased by research analysts at HC Wainwright from $38.00 to $30.00 in a report released on Thursday, The Fly reports. HC Wainwright’s price objective indicates a potential upside of 402.51% from the company’s previous close.

A number of other analysts also recently issued reports on the company. Zacks Investment Research raised Personalis from a “sell” rating to a “hold” rating in a research note on Saturday, April 23rd. Bank of America upgraded Personalis from a “neutral” rating to a “buy” rating and dropped their price objective for the company from $27.00 to $23.00 in a report on Friday, January 7th. Citigroup lowered their target price on Personalis from $30.00 to $18.00 and set a “buy” rating for the company in a report on Friday, February 25th. BTIG Research reiterated a “buy” rating and issued a $30.00 target price on shares of Personalis in a report on Friday, January 7th. Finally, Oppenheimer lowered their target price on Personalis from $30.00 to $24.00 and set an “outperform” rating for the company in a report on Friday, February 25th. Three investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company. Based on data from MarketBeat.com, Personalis presently has an average rating of “Buy” and a consensus target price of $25.38.

Shares of NASDAQ:PSNL opened at $5.97 on Thursday. The stock has a market capitalization of $269.78 million, a price-to-earnings ratio of -4.03 and a beta of 1.71. The stock’s 50-day simple moving average is $7.87 and its two-hundred day simple moving average is $11.92. Personalis has a 52-week low of $5.40 and a 52-week high of $28.47.

Personalis (NASDAQ:PSNLGet Rating) last posted its quarterly earnings data on Wednesday, May 4th. The company reported ($0.63) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.57) by ($0.06). Personalis had a negative net margin of 76.29% and a negative return on equity of 19.72%. During the same period in the previous year, the firm earned ($0.29) EPS. As a group, equities analysts forecast that Personalis will post -2.49 earnings per share for the current year.

In other Personalis news, CFO Aaron Tachibana sold 4,511 shares of the stock in a transaction that occurred on Wednesday, March 2nd. The stock was sold at an average price of $10.18, for a total transaction of $45,921.98. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, General Counsel Stephen Michael Moore sold 5,733 shares of the stock in a transaction that occurred on Monday, May 2nd. The shares were sold at an average price of $5.53, for a total value of $31,703.49. Following the transaction, the general counsel now directly owns 76,381 shares of the company’s stock, valued at approximately $422,386.93. The disclosure for this sale can be found here. Insiders have sold 10,715 shares of company stock worth $82,420 in the last quarter. 7.50% of the stock is currently owned by company insiders.

Large investors have recently added to or reduced their stakes in the stock. Millennium Management LLC lifted its holdings in Personalis by 533.6% during the 4th quarter. Millennium Management LLC now owns 1,350,852 shares of the company’s stock worth $19,277,000 after buying an additional 1,137,636 shares during the last quarter. BlackRock Inc. increased its position in Personalis by 24.3% in the 4th quarter. BlackRock Inc. now owns 4,389,333 shares of the company’s stock valued at $62,637,000 after acquiring an additional 857,372 shares during the period. ARK Investment Management LLC increased its position in Personalis by 6.1% in the 1st quarter. ARK Investment Management LLC now owns 5,184,784 shares of the company’s stock valued at $42,463,000 after acquiring an additional 296,669 shares during the period. Point72 Asset Management L.P. purchased a new stake in Personalis in the 3rd quarter valued at approximately $3,095,000. Finally, Norges Bank purchased a new stake in Personalis in the 4th quarter valued at approximately $1,424,000. Hedge funds and other institutional investors own 86.47% of the company’s stock.

Personalis Company Profile (Get Rating)

Personalis, Inc operates as a cancer genomics company worldwide. The company provides sequencing and data analysis services to support the development of cancer therapies and large-scale genetic research programs. It offers NeXT Platform, which provides data analysis for tumor and its immune microenvironment, from a single limited tissue or plasma sample; ImmunoID Next for tumor profiling from tissue; NeXT Liquid Biopsy for tumor profiling from plasma; NeXT Personal, a liquid biopsy offering for personalized tumor tracking for patients; NeXT Dx Test, a genomic cancer profiling test enabling composite biomarkers for cancer treatment; and NeXT SHERPA and NeXT NEOPS for neoantigen prediction capabilities.

Further Reading

The Fly logo

Analyst Recommendations for Personalis (NASDAQ:PSNL)

Receive News & Ratings for Personalis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Personalis and related companies with MarketBeat.com's FREE daily email newsletter.